Status:
RECRUITING
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Alpha-1 Foundation
Conditions:
Alpha 1-Antitrypsin
COPD
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase ris...
Eligibility Criteria
Inclusion
- Adults who are heterozygous for a SERPINA1 Z allele
- Have either had no COPD exacerbations or 2 or more exacerbations in the previous year
- Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine in the past
Exclusion
- Received a pneumococcal conjugate vaccine within the past 5 years
- Known allergy, severe adverse reaction, or other sensitivity to pneumococcal conjugate vaccines
Key Trial Info
Start Date :
September 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07135427
Start Date
September 3 2025
End Date
June 1 2027
Last Update
November 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294